(Health Korea News / Changyong Lee) NGenBio announced in a public announcement on the 26th that the board of directors decided to increase paid-in capital to shareholders worth 16 billion won.
EnGenBio’s paid-in capital increase is the first since its listing. After shareholder allocation, forfeited shares will be held through a general public offering. 6 million shares, equivalent to 46.6% of the total 12,889,227 shares, will be issued as new shares. LS Securities served as the lead underwriter. The expected issue price is 2,710 won.
NGenBio will use the funds secured through this paid-in capital increase to ▲ capital investment in a subsidiary to expand the business of the US CLIA lab acquired in the first half of 2024, ▲ research and development, such as development of companion diagnosis and AI-based diagnostic software and NGS tuberculosis product development, and ▲ expansion of sales. It is planned to be used to secure operating funds, including raw material costs, and to repay existing convertible bonds.
Choi Dae-chul, CEO of ENGENBIO, said, “We have decided to increase capital to expand new test items such as NGS in our US CLIA lab and strengthen competitiveness.” He added, “The secured funds will be used to expand domestic and overseas business and secure growth engines.” “It is planned and will also contribute to strengthening financial soundness,” he said.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
